ライフサイエンスコーパス: hydroxybutyrate

1 yl-CoA), butyryl CoA, acetoacetate, and beta-hydroxybutyrate.

2 eps from commercially available methyl (R)-3-hydroxybutyrate.

3 the high metabolic burden-biopolymer poly-3-hydroxybutyrate.

4 ormations found in model compounds of poly-4-hydroxybutyrate.

5 dogenous ligand for the receptor may be beta-hydroxybutyrate.

6 thyl (R)-3-hydroxydecanoate and methyl (R)-3-hydroxybutyrate.

7 d urea at physiological pH, but not for beta-hydroxybutyrate.

8 inability of the hbd mutant to grow on beta-hydroxybutyrate.

9 atalyze the oxidation of the ketone body d-3-hydroxybutyrate.

10 and glucose, or glucose plus insulin or beta-hydroxybutyrate.

11 it is also induced by both enantiomers of 3-hydroxybutyrate.

12 with no increase in free fatty acids or beta-hydroxybutyrate.

13 together with increases in the ketone body 3-hydroxybutyrate.

14 , with different properties and without beta-hydroxybutyrate.

15 hentic (2R,3R)- and (2R,3S)-2,3-dideuterio-2-hydroxybutyrate.

16 (epoxypropane) to form acetoacetate and beta-hydroxybutyrate.

17 of the endogenous storage compound poly-beta-hydroxybutyrate.

18 after direct ventricular application of beta-hydroxybutyrate.

19 ith increased myocardial utilization of beta-hydroxybutyrate.

20 th medium also increased the yield of poly-3-hydroxybutyrate.

21 observed on exogenous administration of beta-hydroxybutyrate.

22 tent) of glucose, free fatty acids, and beta-hydroxybutyrate.

23 a transporter of the major ketone body beta-hydroxybutyrate.

24 tyl neuraminic acid, 3-hydroxyisobutyrate, 3-hydroxybutyrate/3-aminoisobutyrate, tyrosine, valine and

25 ation step, showed that it was composed of 3-hydroxybutyrate (3HB) (60%) and 3-hydroxyvalerate (3HV)

26 83 x 10(-2) +/- 1.25 x 10(-2) s(-1)) or beta-hydroxybutyrate (4.11 x 10(-2) +/- 0.62 x 10(-2) s(-1)).

27 variant CPS lacking one methyl group on the hydroxybutyrate, 4-(3-hydroxybutanamido)-4,6-dideoxy-d-g

28 her levels of dicarboxylic fatty acids and 2-hydroxybutyrate (a known marker of glucose malabsorption

29 t that, when ingested, is converted to gamma-hydroxybutyrate, a drug of abuse with depressant effects

30 y, isotonic solution (IS) enriched with beta-hydroxybutyrate, a nonlactate-generating substrate, was

31 between C(4) ketogenesis (production of beta-hydroxybutyrate + acetoacetate), C(5) ketogenesis (produ

32 odies are comprised of three compounds (beta-hydroxybutyrate, acetoacetate, and acetone) that circula

33 tly increased the output of 13C-labeled beta-hydroxybutyrate, acetoacetate, and CO2, indicating stimu

34 tine increased synthesis of 13C-labeled beta-hydroxybutyrate, acetoacetate, and N-acetylglutamate.

35 olic (lactate/pyruvate) and mitochondrial (3-hydroxybutyrate/acetoacetate) NADH redox states were ele

36 acetoacetate yields a markedly reduced beta-hydroxybutyrate:acetoacetate ratio of 1:3, compared with

37 We identified eight metabolites (3-D-hydroxybutyrate, acetone, acetoacetate, citrate, lactate

38 activation of the 3-hydroxyl of HBCoA (or a hydroxybutyrate acyl enzyme) for nucleophilic attack on

39 content and 2-fold increases in plasma beta-hydroxybutyrate, acylcarnitines, and hepatic mRNA expres

40 The serum metabolite alpha-hydroxybutyrate (AHB) is increasingly recognized as a re

41 a from nondiabetic subjects identified alpha-hydroxybutyrate (alpha-HB) and linoleoyl-glycerophosphoc

42 abolic substrates pyruvate, acetoacetate, or hydroxybutyrate also prevented mitochondrial failure and

43 lar rescue through increased amounts of beta-hydroxybutyrate, an endogenous HDACi.

44 l syndrome suggesting toxic effects of gamma-hydroxybutyrate and a history of ingesting 1,4-butanedio

45 Hydroxybutyrate and acetoacetate (AC), alone or in combi

46 ting enzyme for myocardial oxidation of beta-hydroxybutyrate and acetoacetate.

47 These metabolites were identified as beta-hydroxybutyrate and acetoacetate.

48 In particular, increased concentrations of 3-hydroxybutyrate and alanine and reduced concentrations o

49 ma-butyrolactone, another precursor of gamma-hydroxybutyrate and an industrial solvent, began to be m

50 cetate, adenosine, xanthine, acetoacetate, 3-hydroxybutyrate and betaine in alcohol-fed mice and decr

51 tion of four-carbon beta-hydroxyacids like d-hydroxybutyrate and d-threonine.

52 ease the efficacy of the endogenous ligand 3-hydroxybutyrate and enhance its potency almost 10-fold.

53 similar to those of its counterparts, gamma-hydroxybutyrate and gamma-butyrolactone.

54 Complexes of poly-(R)-3-hydroxybutyrate and inorganic polyphosphate (PHB/polyP),

55 After reports of toxic effects of gamma-hydroxybutyrate and its resultant regulation by the fede

56 ing mechanisms by testing the effect of beta-hydroxybutyrate and octanoate on rat hippocampal synapti

57 ions were used to assess the ability of beta-hydroxybutyrate and octanoate to support neuronal activi

58 ratory quotient, together with elevated beta-hydroxybutyrate and reduced plasma fatty acid levels, su

59 Two metabolic intermediates, gamma-hydroxybutyrate and succinic semialdehyde, inactivated t

60 cerebral dysfunction of subjects ingesting 4-hydroxybutyrate and to the mental retardation of patient

61 ranes, and consisting of a complex of poly(3-hydroxybutyrate) and calcium polyphosphate.

62 h both hyperketonemia (acetoacetate and beta-hydroxybutyrate) and hyperglycemia.

63 Ketone bodies, 3-hydroxybutyrate, and acetoacetate, were nonstatistically

64 elevations in gamma-aminobutyric acid, gamma-hydroxybutyrate, and homocarnosine, and low glutamine.

65 plasma and liver triglycerides, plasma beta-hydroxybutyrate, and insulin.

66 McCarey-Kaufman medium, with or without beta-hydroxybutyrate, and other known media (Optisol and Liko

67 d reduced body weight, increased plasma beta-hydroxybutyrate, and reduced plasma insulin compared wit

68 ivatives, hydroxysteroids, alcohols and beta-hydroxybutyrate, and the capacity to bind amyloid-beta p

69 Amino acids, beta-hydroxybutyrate, and tricarboxylic acid cycle intermedia

70 amino acids, nonesterified fatty acids, beta-hydroxybutyrate, and urinary nitrogen but no change in b

71 Further, the ketone body beta-hydroxybutyrate, another metabolite that impacts redox s

72 he O-2 of the sugar ring and at the C-3 of 3-hydroxybutyrate are not essential for induction of cross

73 s supplemented with (R)-3-hydroxybutyl (R)-3-hydroxybutyrate as 30% of calories.

74 When placed in medium with d-beta-hydroxybutyrate as the principal energy substrate, COS c

75 ction of the fluorinated diketide 2-fluoro-3-hydroxybutyrate at approximately 50 % yield.

76 beta-Hydroxybutyrate augmented insulin secretion in human isl

77 PE cells, like hepatocytes, can produce beta-hydroxybutyrate (beta-HB) from fatty acids.

78 We found increased levels of beta-hydroxybutyrate (beta-HB) in the apical medium following

79 the vitamin niacin and the ketone body beta-hydroxybutyrate (beta-HB).

80 However, VMH beta-hydroxybutyrate (beta-OHB) and VMH-to-serum beta-OHB rat

81 ients had similar ISR but higher plasma beta-hydroxybutyrate (beta-OHB) levels during L/H infusion an

82 substrates, we examined the effects of beta-hydroxybutyrate (betaHB) on synaptic transmission and mo

83 An increased concentration of beta-hydroxybutyrate (betaHBA) is a key biomarker for diagnos

84 We report that the ketone body d-beta-hydroxybutyrate (betaOHB) is an endogenous and specific

85 The ketone bodies beta-hydroxybutyrate (BHB) and acetoacetate (AcAc) support ma

86 Beta-hydroxybutyrate (BHB) is a ketone body and has recently

87 The ketone body beta-hydroxybutyrate (BHB) is synthesized in the liver from f

88 concentrations of lactate, pyruvate, or beta-hydroxybutyrate (BHB) on the sympathoadrenal response to

89 sting conditions, this mutation reduced beta-hydroxybutyrate (BHB) plasma levels as well as BHB relea

90 to acetate and propionate, we show that beta-hydroxybutyrate (BHB), a metabolite produced during keto

91 of the ketone bodies acetoacetate (AA), beta-hydroxybutyrate (BHB), and acetone (ACE).

92 lytical device (pop-up-EPAD) to measure beta-hydroxybutyrate (BHB)-a biomarker for diabetic ketoacido

93 vated levels of acetoacetate (AcAc) and beta-hydroxybutyrate (BHB).

94 th ketone bodies (acetoacetate [AA] and beta-hydroxybutyrate [BHB]) in the presence or absence of hig

95 ylalanine, tyrosine, valine, glycerol, beta -hydroxybutyrate (BHBA), and acetate were predicted less

96 s of hepatic PEPCK mRNA, blood glucose, beta-hydroxybutyrate, blood urea nitrogen, and gluconeogenesi

97 nd that physiological concentrations of beta-hydroxybutyrate (BOH) induced proteolysis in cells maint

98 , as validated by parallel venous blood beta-hydroxybutyrate (BOHB) measurements.

99 efficient method for the synthesis of poly(3-hydroxybutyrate) by the carbonylative polymerization of

100 hysiological measurements indicate that beta-hydroxybutyrate causes an increase in neurotransmitter r

101 class with commercial applicability, poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) can be prod

102 e also tested for the coproduction of poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) coupled wit

103 propriate substrate, the copolymer poly(beta-hydroxybutyrate-co-beta-hydroxyvalerate) (PHBV).

104 ation enzyme activity and portal plasma beta-hydroxybutyrate concentration without significantly affe

105 to beta-hydroxybutyrate; higher fasting beta-hydroxybutyrate concentration; slower beta-hydroxybutyra

106 levels increased, and free fatty acids and 3-hydroxybutyrate concentrations and the rate of lipolysis

107 The LC diet induced ketosis with mean 3-hydroxybutyrate concentrations of 1.52 mmol/L in plasma

108 try), and ketogenesis (from circulating beta-hydroxybutyrate concentrations).

109 ion, phosphorylation of ACC, and plasma beta-hydroxybutyrate concentrations.

110 er in the presence of the ketone body R-beta-hydroxybutyrate, consistent with earlier findings that k

111 ellular carbon via the 3-hydroxypropionate/4-hydroxybutyrate cycle (3HP/4HB).

112 pathway suggests that the hydroxypropionate/hydroxybutyrate cycle emerged independently in Crenarcha

113 version of the autotrophic hydroxypropionate/hydroxybutyrate cycle of Crenarchaeota that is far more

114 crenarchaeota) use the 3-hydroxypropionate/4-hydroxybutyrate cycle to assimilate CO2 into cell materi

115 hway in the form of the 3-hyroxypropionate/4-hydroxybutyrate cycle were identified.

116 oxylate bypass and the 3-hydroxypropionate/4-hydroxybutyrate cycle were observed.

117 the fatty acid-derived ketone body (D)-beta-hydroxybutyrate ((D)-beta-OHB) specifically activates PU

118 that the infusion of the ketone body d-beta-hydroxybutyrate (DbetaHB) in mice confers partial protec

119 f cellular energy with a ketone body, D-beta-hydroxybutyrate, decreased rotenone toxicity in MN9D cel

120 (R)-3-Hydroxybutyrate dehydrogenase (BDH) is a lipid-requiring

121 (R)-3-Hydroxybutyrate dehydrogenase (BDH) is a lipid-requiring

122 g pathway were enriched, i.e. SLC22A17 and 3-hydroxybutyrate dehydrogenase (BDH2).

123 In addition, a gene encoding beta-hydroxybutyrate dehydrogenase (hbd) was identified.

124 Conversely, expression of beta-hydroxybutyrate dehydrogenase 1, a key enzyme in the ket

125 me differs from all the presently known beta-hydroxybutyrate dehydrogenases which are well establishe

126 For the 3-hydroxyisobutyrate- and 3-hydroxybutyrate derived enolates, the catalyst-controlle

127 he identification and verification of a beta-hydroxybutyrate-derived protein modification, lysine bet

128 ts, while the degradation of glucose or beta-hydroxybutyrate did not.

129 el sulphonium compound 4-dimethylsulphonio-2-hydroxybutyrate (DMSHB), which is oxidatively decarboxyl

130 The time courses of acetoacetate and beta-hydroxybutyrate formaton indicate that acetoacetate is t

131 amphiphilic, solvating polyester, poly-(R)-3-hydroxybutyrate, frequently associated with polyP.

132 thylenedioxymethamfetamine, ephedrine, gamma-hydroxybutyrate; gamma-butyrolactone, 1,4-butanediol, fl

133 Overdose of gamma-hydroxybutyrate (GHB) frequently causes respiratory depr

134 gamma-Hydroxybutyrate (GHB) naturally occurs in the brain, but

135 ith normal human islets, we found that gamma-hydroxybutyrate (GHB), a potent inhibitory neurotransmit

136 estigate, in normal young men, whether gamma-hydroxybutyrate (GHB), a reliable stimulant of slow-wave

137 t sample was thermally desorbed sodium gamma-hydroxybutyrate (GHB), and the second sample was a liqui

138 ey are derived from the drugs of abuse gamma-hydroxybutyrate (GHB), gamma-hydroxypentanoate(GHP), in

139 reased central nervous system GABA and gamma-hydroxybutyrate (GHB).

140 the biosynthesis of the neuromodulator gamma-hydroxybutyrate (GHB).

141 including arabinose, malate, succinate, beta-hydroxybutyrate, glycerol, formate, and galactose.

142 ed from lactate, 3-hydroxyisobutyrate, and 3-hydroxybutyrate have been investigated.

143 omposed of two monomers in which the growing hydroxybutyrate (HB) chain alternates between C149 on ea

144 (HB-CoA) have been used to detect oligomeric hydroxybutyrate (HB) units covalently bound to the synth

145 KPD had slower acetyl CoA conversion to beta-hydroxybutyrate; higher fasting beta-hydroxybutyrate con

146 In vivo oxidation of (13)C-labeled beta-hydroxybutyrate in neonatal Oxct1(-/-) mice, measured us

147 tin regulation and diverse functions of beta-hydroxybutyrate in the context of important human pathop

148 Blood beta-hydroxybutyrate in the KLC dieters was 3.6 times that in

149 sure 1,4-butanediol or its metabolite, gamma-hydroxybutyrate, in urine, serum, or blood.

150 application of pyruvate, iodoacetate or beta-hydroxybutyrate induced electromechanical and [Ca2+]i tr

151 propylene oxide carboxylation and that beta-hydroxybutyrate is a secondary product formed by the red

152 Since beta-hydroxybutyrate is both a major fuel and a signaling mol

153 We have discovered that the action of beta-hydroxybutyrate is specifically upon HDAC2 and HDAC3, wh

154 As in R. etli, a 4-carbon fatty acid, beta-hydroxybutyrate, is esterified to (omega - 1) of the LCF

155 Changes in beta-hydroxybutyrate, isoleucine, lactate, and pyridoxate wer

156 n, elevated fatty acid oxidation, and 3-beta-hydroxybutyrate ketone levels, and reduced appetite-stim

157 production of the fat breakdown product beta-hydroxybutyrate, leading to increased production of pros

158 n kinase B) and the ability to suppress beta-hydroxybutyrate levels are not impaired in TGN.

159 so produced higher free fatty acids and beta-hydroxybutyrate levels compared with placebo.

160 tically induced in response to elevated beta-hydroxybutyrate levels in cultured cells and in livers f

161 Blood d-beta-hydroxybutyrate levels in the KE group were 3-5 times th

162 enhanced; in patients with T2D, fasting beta-hydroxybutyrate levels rose from 246 +/- 288 to 561 +/-

163 Plasma 3-beta-hydroxybutyrate levels were increased 3-5 days after inf

164 acid oxidation, as inferred from serum beta-hydroxybutyrate levels, was increased in response to fas

165 l antibody normalized blood glucose and beta-hydroxybutyrate levels.

166 y changes in plasma free fatty acid and beta-hydroxybutyrate levels.

167 ve gained depsipeptide (D-Ala-D-Lac, D-Ala-D-hydroxybutyrate) ligase activity with dipeptide/depsipep

168 he acetyl moiety of citrate, C-1 + 2 of beta-hydroxybutyrate, malonyl-CoA, and acetylcarnitine.

169 etic modifications through elevation of beta-hydroxybutyrate may provide a feasible strategy to treat

170 owing an epigenetic switch triggered by beta-hydroxybutyrate-mediated inhibition of HDAC3.

171 cellular depolymerases), as well as PhaZ2 (a hydroxybutyrate oligomer hydrolase).

172 ogical concentrations of ketone bodies (beta-hydroxybutyrate or acetoacetate) reduced the spontaneous

173 decreased in the presence of insulin or beta-hydroxybutyrate or both (from 1.14 +/- 0.3 to 0.58 +/- 0

174 y inhibited in hepatocytes incubated in beta-hydroxybutyrate or fatty acids, and the observed inhibit

175 thylamphetamine (MDMA), 221 (10%) used gamma-hydroxybutyrate or gamma-butyrolactone, 175 (8%) used me

176 cose, free fatty acids (FFAs), lactate, beta-hydroxybutyrate, or insulin levels relative to controls,

177 e mitochondrial complex II activator, D-beta-hydroxybutyrate, or the anti-apoptotic bile acid taurour

178 8 +/- 0.16 [insulin], to 0.75 +/- 0.17 [beta-hydroxybutyrate] or to 0.53 +/- 0.17 [both], P < 0.05).

179 2 micromol.kg(-1).min(-1)), net hepatic beta-hydroxybutyrate output (0.1 +/- 0.0 and 0.4 +/- 0.1 micr

180 a-hydroxybutyrate concentration; slower beta-hydroxybutyrate oxidation; faster leucine oxidative deca

181 ate step two by coupling oxidation of poly(3-hydroxybutyrate) (P3HB) to NO2(-) reduction.

182 f the new absorbable polymer scaffold poly-4-hydroxybutyrate (P4HB) in complex abdominal wall reconst

183 were closed with polyglactin 910 and poly-4 hydroxybutyrate (P4HB) sutures in opposite halves of the

184 beta-Hydroxybutyrate permeability was not increased above bac

185 Poly-3-hydroxybutyrate (PHB) and bacterial cellulose (BC) are b

186 onproteinaceous polymers, namely, poly-(R)-3-hydroxybutyrate (PHB) and inorganic polyphosphate (polyP

187 opha produces both the homopolymer poly-beta-hydroxybutyrate (PHB) and, when provided with the approp

188 ultative methylotroph, accumulates poly-beta-hydroxybutyrate (PHB) as a carbon and energy reserve mat

189 meliloti stores carbon and energy in poly-3-hydroxybutyrate (PHB) as a contingency against carbon sc

190 gions containing genes involved in poly-beta-hydroxybutyrate (PHB) biosynthesis and degradation and a

191 store excess carbon as intracellular poly-3-hydroxybutyrate (PHB) granules that assist survival unde

192 To evaluate if the compound poly-beta-hydroxybutyrate (PHB) might be a suitable immunoprophyla

193 idly under mild conditions to produce poly(3-hydroxybutyrate) (PHB) and poly(3-hydroxyvalerate) (PHV)

194 Numerous bacteria accumulate poly(3-hydroxybutyrate) (PHB) as an intracellular reservoir of

195 Poly(3-hydroxybutyrate) (PHB) is well-known as a high molecular

196 e to dissolve these compounds in molten poly(hydroxybutyrate) (PHB), having a hydroxyvalerate co-mono

197 rades the carbon storage molecule poly((R)-3-hydroxybutyrate) (PHB).

198 the above, the potential of using the poly(3-hydroxybutyrate), PHB, depolymerase from Psuedomonas lem

199 s copurify with two homopolymers, poly[(R)-3-hydroxybutyrate] (PHB) and inorganic polyphosphate (poly

200 Intracellular poly[D-(-)-3-hydroxybutyrate] (PHB) depolymerases degrade PHB granule

201 h an emphasis on the synthesis of poly[(R)-3-hydroxybutyrate] (PHB), a renewable biodegradable PHA po

202 herichia coli complexed with a D-Ala-D-alpha-hydroxybutyrate phosphonate and the structure of the Y21

203 Disruption of beta-hydroxybutyrate production increases hepatic NAD(+)/NADH

204 erol was directly correlated with blood beta-hydroxybutyrate (r = 0.297, P = 0.025).

205 The K(m)s for NAD+ and (R)-3-hydroxybutyrate (R-HOB) of expressed BDH are similar to

206 of calories as corn starch, palm oil, or R-3-hydroxybutyrate-R-1,3-butanediol monoester (3HB-BD ester

207 asured the effects of a diet in which D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester [ketone est

208 Three pathways, 2-hydroxybutyrate-related metabolites, gamma-glutamyl dipe

209 rsely associated with 5 metabolites in the 2-hydroxybutyrate-related subpathway and positively associ

210 wer than wild-type hepatocytes, whereas beta-hydroxybutyrate release was increased 2-fold, supporting

211 hydrogenase, high plasma concentrations of 4-hydroxybutyrate result in high concentrations of 4-hydro

212 ere seeded onto poly (glycolic acid)/poly (4-hydroxybutyrate) scaffolds for 5 days.

213 d with activation of the renoprotective beta-hydroxybutyrate signaling pathway.

214 Inhibition of beta-hydroxybutyrate signalling or prostaglandin production s

215 In hippocampal slices beta-hydroxybutyrate supported synaptic transmission under lo

216 f SCOT-KO mice diminish de novo hepatic beta-hydroxybutyrate synthesis by 90%.

217 serum concentrations of fatty acids and beta-hydroxybutyrate than control mice, regardless of whether

218 nts in persistent AF revealed a rise in beta-hydroxybutyrate, the major substrate in ketone body meta

219 NTHi P5 associates with polyP and poly-(R)-3-hydroxybutyrate to create large, cation-selective pores

220 ivity, and reduced H2S levels; however, beta-hydroxybutyrate treatment had no effect.

221 nd higher rates of methamphetamine and gamma hydroxybutyrate use when compared to young MSM who teste

222 activity in villus tip cells and plasma beta-hydroxybutyrate values in portal vein and carotid artery

223 , as well as portal and arterial plasma beta-hydroxybutyrate values, were determined.

224 lus glutamine, or methyl succinate plus beta-hydroxybutyrate was also decreased in the PC knockdown c

225 eucine, valine, alanine, and alpha- and beta-hydroxybutyrate were found to have decreased concentrati

226 Serum concentrations of beta-hydroxybutyrate were greater with MCTs plus LCTs than wi

227 of insulin, glucose, FFAs, lactate, and beta-hydroxybutyrate were normal.

228 Plasma and urinary beta-hydroxybutyrate were similar on both diets.

229 s a high molecular weight homopolymer of R-3-hydroxybutyrate which accumulates in storage granules wi

230 The metabolite beta-hydroxybutyrate, which increases after prolonged exercis

231 etylmuramic acid product to 2,3-dideuterio-2-hydroxybutyrate, which was shown to be (2R) by enzymatic

232 lucose to alternative fuels, lactate or beta-hydroxybutyrate, while monitoring the spontaneous firing

233 n all lines was achieved by combining d-beta-hydroxybutyrate with tauroursodeoxycholic acid but not w